Gilead Sciences said total revenues for Q3 2025 increased 3% compared to the same period in 2024 to $7.8 billion. Product sales decreased 2% to $7.3 billion, with the company citing lower Veklury and Cell Therapy sales as the primary drivers.

1. 01

   Gilead Sciences said total revenues for Q3 2025 increased 3% compared to the same period in 2024 to $7.8 billion. Product sales decreased 2% to $7.3 billion, with the company citing lower Veklury and Cell Therapy sales as the primary drivers.

2. 02

   Gilead Sciences said diluted EPS for Q3 2025 was $2.43, up from $1.00 in the same period in the prior year, and non-GAAP diluted EPS was $2.47 compared to $2.02 in the same period in the prior year. The company cited the non-recurrence of an IPR&D impairment charge of $1.75 billion recorded in the prior year as a driver of the GAAP increase.

3. 03

   Gilead Sciences said HIV product sales for Q3 2025 increased 4% to $5.3 billion, with Biktarvy sales increasing 6% to $3.7 billion. The company cited higher demand and favorable inventory dynamics as factors, partially offset by lower average realized price.

4. 04

   Gilead Sciences said it generated operating cash flow of $4.1 billion during Q3 2025, paid dividends of $1.0 billion and repurchased $435 million of common stock. As of September 30, 2025, cash, cash equivalents and marketable debt securities were $9.4 billion.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.